Original Article

Significant association factors of bone mineral density in Taiwan adults

Tzy-Ling Chuang\textsuperscript{b}, Mei-Hua Chuang\textsuperscript{d}, Chun-Hung Lin\textsuperscript{e}, Shih-Chin Chou\textsuperscript{a}, Yuh-Feng Wang\textsuperscript{a,b, f}*

\textsuperscript{a}Department of Nuclear Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, \textsuperscript{b}Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien, Taiwan, \textsuperscript{c}Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, \textsuperscript{d}Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien, Taiwan, \textsuperscript{e}Department of General Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, Center of Preventive Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

\textbf{ABSTRACT}

\textbf{Objective:} To examine the biofactors associated with bone mineral density (BMD) in southern Taiwanese adults. \textbf{Materials and Methods:} The medical records of 3242 adults who underwent health examinations between June 2014 and February 2018 at a regional hospital in southern Taiwan were reviewed. The data collected included health history, anthropomorphic characteristics, clinical laboratory results, biochemical parameters, and BMD. The data were used to identify the biofactors associated with BMD/T-scores at the lumbar spine and femoral neck by multivariate linear regression analysis with the stepwise method. \textbf{Results:} The mean age of the patients was 58.1 years, and 71.4\% were male. Factors positively correlated with BMD and the T-score included body mass index (BMI), male gender, calcium, and creatinine. Age, alkaline phosphatase (ALP), triiodothyronine, serum thyroxine, low-density lipoprotein cholesterol, and a history of hyperlipidemia were negatively correlated with BMD and the T-score. \textbf{Conclusion:} The associated biofactors reported here were similar to and had similar relationships as the biofactors identified in previous literature reports. Not all of the sites examined for BMD were influenced by the same association factors, except for BMI, male gender, age, and ALP, implying that the bone remodeling processes that shape BMD involve a complex regulatory network and demonstrating that our extracted factors are the most useful for clinical practice.

\textbf{Keywords:} Bone mineral density, Factors, Health examination, Taiwan, T-score

\textbf{INTRODUCTION}

Osteoporosis is accompanied by an imbalance between bone resorption and bone formation, which are two facets of the bone turnover process [1]. The loss of bone mass is linked to the development of fractures and subsequent disability and is an important cause of morbidity and mortality [2,3]. To develop interventions to increase the bone mineral density (BMD) and to reduce and prevent fractures, it is important to elucidate the variables predicting these factors.

Several variables, including aging, menopause status, metabolic and endocrine diseases, inadequate physical activity, body mass index (BMI), smoking, Vitamin D deficiency, thyroid function, serum ferritin levels, and a family history of osteoporosis, have been proposed to be associated with BMD changes in elderly subjects [2,4-6]. In our study, we expanded the age range to include south Taiwanese adults and included the clinical histories and laboratory data from health examinations as variability biofactors.

Our aim was to determine how demographic, biochemical, and clinical features are related to BMD at specific sites, including the bilateral femoral neck and lumbar spine.

\textbf{MATERIALS AND METHODS}

\textbf{Subjects}

A retrospective study was conducted on all the adults who underwent health examinations between June 2014 and February 2018 at the preventive medical center of a regional teaching hospital in southern Taiwan. Subjects who previously had thyroid disease or underwent internal fixation or total hip replacement at the sites where BMD was measured were excluded. Medical records included (1) history regarding disease, such as hypertension, diabetes mellitus, hyperlipidemia, kidney disease, hepatitis B, and cardiovascular disease; (2) history regarding habits, such as smoking and drinking; and (3) anthropomorphic characteristics (age, sex, height, weight, and BMI). This retrospective study was approved by the Institutional Review Board of the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (No. B10601012), and the waiver of informed consent from each patient was also approved.

\textbf{Access this article online}

\begin{tabular}{|l|}
\hline
Quick Response Code: \\
\hline
Website: www.tcmjmed.com \\
\hline
DOI: 10.4103/tcmj.tcmj_113_19 \\
\hline
\end{tabular}

\section*{How to cite this article:} Chuang TL, Chuang MH, Lin CH, Chou SC, Wang YF. Significant association factors of bone mineral density in Taiwan adults. Tzu Chi Med J 2020; 32(4): 367-72.
Laboratory data

The clinical laboratory findings collected during the health examination included total cholesterol (TCH), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), glucose level before meal, alkaline phosphatase (ALP), calcium, systolic blood pressure (SBP), diastolic blood pressure (DBP), triiodothyronine (T3), serum thyroxine (T4), thyroid-stimulating hormone (TSH), blood urea nitrogen (BUN), creatinine (Cre), and hemoglobin (Hb).

Bone mineral density

BMD was assessed by dual-energy X-ray absorptiometry (DXA) using a Discovery Wi DXA system (Hologic Inc.). Absolute BMD values and T-scores (number of standard deviations below the BMD of a young normal reference group, Asia database) were calculated for all patients. The measured areas included the lumbar spine and the femoral neck regions of the hips bilaterally. The same densitometer was used for all patients to ensure accurate comparisons. For comparison, we divided the study participants into three groups: normal (the lowest T-score −2.5 or less at any site), osteopenia (the lowest T-score between −1 and −2.5 at any site), and osteoporosis (the lowest T-score −2.5 or less at any site).

Table 1: Characteristics of the normal bone mineral density, osteopenia, and osteoporosis subgroup participants

|                      | Normal | Osteopenia | Osteoporosis | P       |
|----------------------|--------|------------|--------------|---------|
| n                    | 921    | 1811       | 510          |         |
| Male (%)             | 785 (85.2) | 1336 (73.8) | 193 (37.8)   | <0.001* |
| Smoking (%)          | 74 (8.0)  | 88 (4.9)   | 7 (1.4)      | <0.001* |
| Drinking (%)         | 190 (20.6) | 272 (15.0)| 40 (7.8)     | <0.001* |
| Hypertension (%)     | 246 (26.7) | 480 (26.5) | 149 (29.2)   | 0.464   |
| Diabetes mellitus (%)| 83 (9.0)  | 183 (10.1)| 45 (8.8)     | 0.534   |
| Hyperlipidemia (%)   | 59 (6.4)  | 129 (7.1)  | 37 (7.3)     | 0.749   |
| Renal disease (%)    | 17 (1.8)  | 29 (1.6)   | 9 (1.8)      | 0.889   |
| Hepatitis B (%)      | 133 (14.4) | 247 (13.6)| 63 (12.4)    | 0.545   |
| Cardiovascular disease (%) | 130 (14.1) | 327 (18.1)| 156 (30.6)   | <0.001* |
| Age (years)          | 54.2±11.5 | 58.6±10.6 | 63.2±9.0     | <0.001* |
| Height (cm)          | 168.0±7.1 | 163.8±7.2 | 158.3±7.1    | <0.001* |
| Weight (kg)          | 73.0±12.2 | 65.0±10.0 | 56.8±8.6     | <0.001* |
| BMI (kg/m²)          | 25.8±3.5  | 24.1±3.1  | 22.6±3.1     | <0.001* |
| TCH (mg/dL)          | 178.4±35.1 | 181.8±38.3 | 182.2±35.8 | 0.052 |
| LDL-C (mg/dL)        | 116.3±29.8 | 118.3±33.0 | 115.7±30.9 | 0.132 |
| HDL-C (mg/dL)        | 43.3±11.9  | 45.7±13.6 | 51.7±15.6    | <0.001* |
| Triglycerides (mg/dL)| 134.3±81.4 | 125.1±74.0 | 109.2±65.4  | <0.001* |
| Glucose (mg/dL)      | 107.6±24.3 | 107.0±21.7 | 105.8±21.1  | 0.333 |
| ALP (IU/L)           | 79.9±23.5  | 85.5±23.9 | 95.6±39.0    | <0.001* |
| Calcium (mmol/L)     | 2.25±0.10  | 2.24±0.10 | 2.24±0.10    | 0.082   |
| SBP (mmHg)           | 130.7±19.1 | 129.4±19.9 | 127.7±20.6  | 0.028* |
| DBP (mmHg)           | 78.0±11.3  | 76.7±11.4 | 73.3±11.6    | <0.001* |
| T3 (ng/mL)           | 0.99±0.18  | 1.0±0.18  | 1.0±0.3      | 0.488   |
| T4 (µg/dL)           | 8.1±1.6    | 8.2±1.6   | 8.6±1.6      | <0.001* |
| TSH (µIU/mL)         | 2.20±1.40  | 2.56±1.12 | 2.43±1.92    | 0.158   |
| BUN (mg/dL)          | 11.6±3.7   | 11.6±3.7  | 11.8±5.6     | 0.681   |
| Cre (mg/dL)          | 1.04±0.30  | 1.00±0.28 | 0.92±0.40    | <0.001* |
| Hb (g/dL)            | 15.1±1.5   | 14.8±1.5  | 14.0±1.3     | <0.001* |

*P<0.05. BMI: Body mass index, TCH: Total cholesterol, LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein cholesterol, ALP: Alkaline phosphatase, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, T3: Triiodothyronine, T4: Serum thyroxine, TSH: Thyroid-stimulating hormone, BUN: Blood urea nitrogen, Cre: Creatinine, Hb: Hemoglobin

Statistical analysis

The results were expressed as the means ± standard deviations or numbers (percentages), as appropriate. Differences in means or frequencies were tested by the Chi-square test or t-test, as appropriate. Multiple linear regression analysis was performed with the BMD and T-score values of each measured site as the dependent variable. The final regression models were developed using stepwise variable selection procedure. All variables listed in Table 1 (except height and weight) were included as independent variables in the initial regression models for evaluation. All statistical analyses were performed using the PASW Statistics, Version 18 program (SPSS Inc., Chicago, IL, USA). A P < 0.05 was considered statistically significant.

RESULTS

Subject characteristics

In total, the medical records of 3242 adults were included, and their demographic and clinical characteristics are presented in Table 1. The study population was predominantly male (71.4%), with a mean age of 58.1 ± 11.0 years. Analysis of clinical characteristics indicated that 27.0% of patients had hypertension, 9.6% were diabetic, 6.9% had hyperlipidemia, 1.7% presented kidney disease, 13.7% had hepatitis B, 18.9%...
had cardiovascular disease, 5.2% were smokers, and 15.5% drank alcohol. There were significant differences between male and female subjects with regard to smoking, drinking, hepatitis B, cardiovascular disease, height, weight, BMI, TCH, HDL-C, TG, ALP, calcium, SBP, DBP, T3, T4, TSH, BUN, Cre, and Hb.

**Bone mineral density**

Mean lumbar spine T-scores on DXA were $-0.43 \pm 1.30$ for men, $-1.31 \pm 1.32$ for women, and $-0.68 \pm 1.36$ for all patients. There were significant differences between male and female subjects in the BMD for the lumbar spine and the femoral neck region of the bilateral hips. Spine and femoral neck T-scores were also significantly different between males and females. There was a higher rate of osteoporosis in the female subjects [Table 2].

**Subgroup characteristics**

There were significant differences among the normal, osteopenia, and osteoporosis subgroups in their percentage of males, smoking, drinking, and cardiovascular disease. Subjects in the osteoporosis subgroup were older and had lower height, lower weight, lower BMI, higher HDL-C, lower TG, higher ALP, lower SBP and DBP, higher T4, lower Cre, and lower Hb [Table 1].

**Multiple linear regressions**

In the analysis of the factors associated with BMD, multivariate linear regression showed that BMD, or the T-score, in some regions was positively correlated with some of the factors, including BMI, male sex, calcium, and Cre, and negatively correlated with other factors, including age, ALP, T3, T4, LDL-C, and hyperlipidemia [Table 3]. Among them, BMI

| Table 2: Demographic and clinical characteristics of study participants |
|-------------------------|----------------|----------------|-----|
|                         | All            | Male           | Female        |   |
|                         | n              | 3242           | 2314          | 928 |
| Age (range) (years)    | 58.1±11.0 (22-89) | 58.0±11.2 (22-89) | 58.4±10.6 (22-89) | 0.315 |
| Smoking (%)            | 169 (5.2)      | 165 (7.1)      | 4 (0.4)       | <0.001* |
| Drinking (%)           | 502 (15.5)     | 475 (20.5)     | 27 (2.9)      | <0.001* |
| Hypertension (%)       | 875 (27.0)     | 633 (27.4)     | 242 (26.1)    | 0.459 |
| Diabetes mellitus (%)  | 311 (9.6)      | 229 (9.9)      | 82 (8.8)      | 0.354 |
| Hyperlipidemia (%)     | 225 (6.9)      | 160 (6.9)      | 65 (7.0)      | 0.927 |
| Kidney disease (%)     | 55 (1.7)       | 41 (1.8)       | 14 (1.5)      | 0.600 |
| Hepatitis B (%)        | 443 (13.7)     | 349 (15.1)     | 94 (10.1)     | <0.001* |
| Cardiovascular disease (%) | 613 (18.9) | 233 (10.1)     | 380 (40.9)    | <0.001* |
| Height (cm)            | 164.1±7.8      | 167.3±6.2      | 156.3±5.4     | <0.001* |
| Weight (kg)            | 65.9±11.7      | 69.3±11.0      | 57.5±8.9      | <0.001* |
| BMI (kg/m²)            | 24.4±3.4       | 24.7±3.3       | 23.5±3.5      | <0.001* |
| TCH (mg/dL)            | 180.9±37.0     | 178.1±36.8     | 187.8±36.7    | <0.001* |
| LDL-C (mg/dL)          | 117.3±31.8     | 116.7±31.7     | 119.0±32.2    | 0.055 |
| HDL-C (mg/dL)          | 46.0±13.8      | 43.4±12.4      | 52.3±14.9     | <0.001* |
| Triglycerides (mg/dL)  | 125.2±75.1     | 130.2±79.1     | 112.8±62.5    | <0.001* |
| Glucose (mg/dL)        | 107.0±22.4     | 107.4±22.8     | 105.9±21.3    | 0.089 |
| ALP (IU/L)             | 85.5±27.2      | 84.2±24.2      | 88.7±33.4     | <0.001* |
| Calcium (mmol/L)       | 2.24±0.10      | 2.24±0.10      | 2.25±0.10     | 0.023* |
| SBP (mmHg)             | 129.5±19.8     | 131.6±19.2     | 124.3±20.4    | <0.001* |
| DBP (mmHg)             | 76.4±11.5      | 78.8±10.9      | 70.7±10.9     | <0.001* |
| T3 (ng/mL)             | 1.00±0.19      | 1.01±0.18      | 0.98±0.22     | 0.011* |
| T4 (µg/dL)             | 8.2±1.6        | 8.1±1.6        | 8.5±1.6      | <0.001* |
| TSH (µIU/mL)           | 2.44±4.7       | 2.29±3.12      | 2.81±7.25     | 0.034* |
| BUN (mg/dL)            | 11.6±4.1       | 12.1±3.8       | 10.5±4.5      | <0.001* |
| Cre (mg/dL)            | 1.00±0.31      | 1.07±0.29      | 0.82±0.29     | <0.001* |
| Hb (g/dL)              | 14.7±1.5       | 15.3±1.3       | 13.4±1.3      | <0.001* |
| L-spine BMD (g/cm²)    | 0.957±0.156    | 0.988±0.148    | 0.878±0.146   | <0.001* |
| L-spine T-score        | −0.68±1.36     | −0.43±1.30     | −1.31±1.32    | <0.001* |
| Right hip neck BMD (g/cm²) | 0.710±0.126 | 0.736±0.122    | 0.647±0.112   | <0.001* |
| Right hip neck T-score | −1.19±1.04     | −1.01±0.98     | −1.63±1.04    | <0.001* |
| Left hip neck BMD (g/cm²) | 0.710±0.126 | 0.735±0.122    | 0.646±0.112   | <0.001* |
| Left hip neck T-score  | −1.19±1.05     | −1.00±0.99     | −1.64±1.04    | <0.001* |
| BMD category           | Normal         | 921 (28.4)     | 785 (33.9)    | 136 (14.7)   | <0.001* |
|                         | Osteopenia     | 1811 (55.9)    | 1336 (57.7)   | 475 (51.2)   | <0.001* |
|                         | Osteoporosis   | 510 (15.7)     | 193 (8.3)     | 317 (34.2)   | <0.001* |

*P<0.05 BMI: Body mass index, TCH: Total cholesterol, LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein cholesterol, ALP: Alkaline phosphatase, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, T3: Triiodothyronine, T4: Serum thyroxine, TSH: Thyroid-stimulating hormone, BUN: Blood urea nitrogen, Cre: Creatinine, Hb: Hemoglobin, BMD: Bone mineral density
Table 3: Multiple linear regression for the data analysis: Correlation between parameters and regional bone mineral density or T-score by multiple regression analysis using the stepwise method

|                | Spine          | Right hip neck | Left hip neck |
|----------------|----------------|----------------|---------------|
|                | BMD            | T score        | BMD           | T score        | BMD           | T score        |
|                | r  | P   | r  | P   | r  | P   | r  | P   | r  | P   | r  | P   |
| BMI (kg/m²)    | 0.278 <0.001 | 0.284 <0.001   | 0.280 <0.001  | 0.295 <0.001  | 0.287 <0.001  | 0.291 <0.001  |
| Sex (male:female=1:0) | 0.255 <0.001 | 0.221 <0.001   | 0.262 <0.001  | 0.211 <0.001  | 0.267 <0.001  | 0.209 <0.001  |
| Calcium (mmol/L) |               |                | 0.033 0.024   | 0.041 0.007   |                |                |
| Cre (mg/dL)    | 0.039 0.020   | 0.044 0.010    |                |                |                |                |
| Age (years)    | −0.105 <0.001 | −0.079 <0.001  | −0.313 <0.001 | −0.288 <0.001 | −0.307 <0.001 | −0.278 <0.001 |
| ALP (µU/L)     | −0.142 <0.001 | −0.176 <0.001  | −0.131 <0.001 | −0.168 <0.001 | −0.131 <0.001 | −0.170 <0.001 |
| T3 (ng/mL)     | −0.060 <0.001 | −0.053 0.001   | −0.033 0.024  | −0.031 0.042  | −0.039 0.009  |                |
| T4 (µg/dL)     |                |                | −0.046 0.003  |                |                |                |
| LDL-C (mg/dL)  |                |                | −0.036 0.016  |                |                |                |
| Hyperlipidemia | −0.043 0.004  | −0.042 0.005   | −0.034 0.020  | −0.035 0.021  |                |                |

Blue color: Positive correlation, Red color: Negative correlation. BMI: Body mass index, LDL-C: Low-density lipoprotein cholesterol, ALP: Alkaline phosphatase, T3: Triiodothyronine, T4: Serum thyroxine, Cre: Creatinine, BMD: Bone mineral density

and male sex were positively correlated with BMD and the T-score at all measured sites, and age and ALP were negatively correlated with BMD and the T-score at all measured sites. T3 was negatively associated with BMD and the T-score at nearly all the measured sites except for the left femoral neck T-score, which showed a negative association with T4. Not all anatomic sites had the same association factors, but their positive or negative correlation was consistent. The parameters and association tendencies were also similar to the ones described in the literature [7-15].

**DISCUSSION**

Traditional risk factors for low BMD include advanced age, female sex, low BMI, smoking, Caucasian race, and glucocorticoids [7]. We confirm that male patients had higher BMD and consistently in all measured sites. A Korean study suggested that aging, waist circumference, BMI, weight training, hypercholesterolemia, hypertriglyceridemia, and diabetes were site specifically associated with BMD in adult men [8]. We expand the population to adults of both sexes; a higher BMI is generally with higher BMD and the T-score at the lumbar and hip sites. The beneficial effect of obesity on BMD has been attributed to the mechanical loading effect of the weight on bone [16]. Increasing calcium intake from dietary sources or taking calcium supplements were found to be significantly associated with increased BMD [17,18]. BMD scores were significantly higher in postmenopausal women, as shown by their T-scores along with increased serum calcium levels [19]. Postmenopausal women, compared to premenopausal women, had a significant reduction in Vitamin D and serum calcium levels, and all of them had low BMD [20]. Low serum calcium and Vitamin D levels were found to be major risk factors associated with osteopenia and osteoporosis among postmenopausal women from slum areas in Ahmedabad [9].

Serum Cre can serve as a marker of muscle mass [10]. Independent of age, a strong positive correlation exists between Cre clearance and bone mass in healthy elderly women [21]. There was a significant linear association between Cre clearance, as measured by the Cockcroft–Gault equation, and glomerular filtration rate, as measured by the Modification of Diet in Renal Disease equation, and hip BMD; however, this association was not observed between serum Cre and BMD [22]. Low serum Cre was independently associated with low BMD in an older population with normal kidney function [10]. Our result showed that both calcium and Cre are positive factors of BMD in our population, which includes Taiwanese adults ranging from 21 to 90 years old.

Bone mass decreases with aging and results in osteoporosis in elderly subjects [2]. ALP is a ubiquitous enzyme that plays an important role in osteoid formation and bone mineralization. It is secreted during osteogenesis and is commonly used to assess osteoblastic activity [23]. An increase in ALP activity in women is associated with more severe osteoporosis [11,24]. Osteocalcin and ALP are valid biomarkers to diagnose low BMD in postmenopausal women [23]. In a group of 3149 healthy Korean men, a negative correlation was found between BMD and ALP [12]. A more specific marker, bone alkaline phosphatase (BAP), was negatively correlated with BMD in Japanese postmenopausal osteoporotic women during denosumab treatment [25]. We confirmed that age and ALP are important negative factors, both generally and consistently in all measured sites, in our population of both men and women.

Thyrotoxicosis accelerates bone remodeling and is one of the known risk factors for osteoporosis [13,26,27]. Subjects with a history of thyroid disease were excluded from our study, because their disease status would have influenced T3, T4, and TSH levels. It was previously shown that thyrotoxicosis causes a remarkable loss of bone mineral mass, which cannot be compensated for after 1 year of successful treatment [28]. Studies of BMD in euthyroid populations indicate that thyroid hormone also regulates bone turnover, and low BMD in a euthyroid population of postmenopausal women was associated with free T4 and free T3 levels but not with TSH [29]. Higher free T4 levels within the physiological reference range, but not low TSH, are independently correlated with low BMD in perimenopausal women [30]. Prolonged treatment with T4 and T3 can directly increase bone resorption in cultured fetal rat long bones [31]. Our study suggested that, even in healthy adults, thyroid function still affects BMD,
especially T3, which is much more potent than T4, in nearly all sites (except left femoral neck T-score) and that there is no relationship between TSH levels and BMD.

Hyperlipidemia increases the risk for generating lipid oxidation products, which accumulate in the subendothelial spaces of the vasculature and bone, impairing bone regeneration and its mechanical strength; thus, these oxidation products may be risk factors for osteoporosis [14,32]. There is an inverse relationship between lumbar spine and whole-body BMD and serum TCH and LDL-C levels in postmenopausal women and HDL-C in premenopausal women [15,33]. Serum lipids, especially low HDL-C and high LDL-C, influence BMD by acting on the long bones and affecting osteoporosis and osteopenia [34]. In a 2018 study of 2,347 male and female participants, TCH and LDL-C had a weak, but significant, negative correlation with the BMD at the sites of the femur and lumbar spine [35]. Plasma LDL-C and HDL-C levels were inversely and positively correlated, respectively, with BMD [36]. Other studies found no significant associations between serum lipid levels and BMD [37,38]. However, in a 2018 meta-analysis of postmenopausal women, the levels of HDL-C, LDL-C, and TCH were higher in the osteoporosis group than in the normal bone density group [39]. Statin use was associated with a significant increase in BMD [40].

The facts that the relationship between BMD changes and many associated factors varied across the different studies may be attributed to study design or to the characteristics of the study’s subjects, such as ethnicity, lifestyle, and demographic features [5,41]. The other factors in our study were not identified as significant independent variables. Although smoking, diabetes, and Hb levels were identified in other studies as factors associated with osteoporosis, our study did not find them to be associated with BMD, probably due to the coexistence of one or more associated factors or due to the involvement of complex regulatory networks in bone modeling.

Our study has certain limitations. First, this is a cross-sectional study. Second, the effects of medications might not have been adequately evaluated by virtue of the study design. However, the parameters that we considered, which included not only the clinical histories but also the laboratory data, reflect the status of the subjects at the time when the study was conducted. Third, because a large number of independent variables were evaluated in the regression models, inflation of Type I error rates is possible. Nevertheless, most of our observed \( P \) values were at \(< 0.001\) rather than near the 0.05 level. Fourth, some factors already known to be associated with BMD, such as iPTH, phosphate, serum 25-hydroxyvitamin D, osteocalcin, BAP, and free T4, were not included in the health examination data. Fifth, our study included both males and females, but the menopausal status was not evaluated. However, we included our population (both male and female and both younger and older adults) and factors (clinical characteristics, habit history, and laboratory data) as much as possible and used stepwise multiple linear regression; the factors significantly affecting BMD and the T-score are summarized in Table 3. In addition, the population size from the general health check is large enough (3242 subjects). In our study, the direction of association was the same across the BMD measurement sites. This study is considered clinically important because it reconfirms the potentially modifiable clinical characteristics for increased or decreased BMD and chooses the most crucial ones among the factors in the literature, thus making them considered most noticeable for use in clinical practice. A better understanding of the key risk factors for low BMD may help reduce the risk of osteoporosis.

**Conclusion**

We evaluate an expansive population and variables simultaneously using the stepwise method. The male patients had higher BMD; hip and L-spine BMD and T-scores were positively correlated with BMI, and some of them were positively correlated with serum calcium and Cre levels. Hip and L-spine BMD and T-scores were negatively associated with age and ALP, and some scores were inversely correlated with T3, T4, and LDL-C. Cases with hyperlipidemia also showed lower value in the hip BMD and T-score. These factors are part of complex regulatory networks that participate in bone modeling and shape BMD. The directions of their associations are consistent; thus, these identified factors can be considered the most significant for clinical practice.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59 (Suppl 1):S2-9.
2. Bliuc D, Nguyen ND, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Accelerated bone loss and increased post-fracture mortality in elderly women and men. Osteoporos Int 2015;26:1331-9.
3. Bliuc D, Nguyen ND, Milich VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21.
4. Wee J, Sng BY, Shen L, Lim CT, Singh G, Das De S. The relationship between body mass index and physical activity levels in relation to bone mineral density in premenopausal and postmenopausal women. Arch Osteoporos 2013;8:162.
5. Heidari B, Hosseini R, Javadian Y, Bijani A, Sateri MH, Nousroodini HG. Factors affecting bone mineral density in postmenopausal women. Arch Osteoporos 2015;10:15.
6. Pinheiro MM, Reis Neto ET, Machado FS, Omura F, Yang JH, Szejnfeld J, et al. Risk factors for osteoporotic fractures and low bone density in pre and postmenopausal women. Rev Saude Publica 2010;44:479-85.
7. Walker M, Grewal HK, Janot A, Yu M, Cenac S, Lannir MR, et al. Assessment of protective factors of bone mineral density in a new orleans sarcoidosis population. #1246. 2014 ACR/ARHP annual meeting. Boston, MA, USA.
8. Lee HS. The factors influencing the bone mineral density in Korean adult men: Based on Korea National Health and Nutrition Examination Survey 2010-2011 data. Korean J Community Nutr 2017;22:136-44.
9. Singh A, Singh H, Patel S. Screening of bone mineral density by densitometer and correlation with serum calcium and Vitamin D levels to detect early osteoporotic changes in postmenopausal women in slum areas of Raipur and Kalupur of Ahmedabad. Int J Basic Clin Pharmacol
10. Huh JH, Choi SI, Lim JS, Chung CH, Shin JY, Lee MY. Lower serum creatinine is associated with low bone mineral density in subjects without overt nephropathy. PLoS One 2015;10:e0133062.

11. Hulth A-G, Nilsson BE, Westlin NE, Wiklund PE. Alkaline phosphatase in women with osteoporosis. Acta Med Scand 1979;206:201-3.

12. Yoon J, Kye S, Lee J, Lee J, Seo J, Park J, et al. Association between alkaline phosphatase with bone mineral density in 50s healthy Korean men. Korean J Fam Pract 2015;5:247-52.

13. Auwerx J, Bouillon R. Mineral and bone metabolism in thyroid disease: A review. Q J Med 1986;60:737-52.

14. Pirih F, Lu J, Ye F, Bezuglyi A, Ati E, Ascenzi MG, et al. Adverse effects of hyperlipidemia on bone regeneration and strength. J Bone Miner Res 2012;27:309-18.

15. Dimic A, Popovic MR, Tasic I, Djordjevic D, Stojanovic S, Stamenkovic B, et al. Relation between body density and certain parameters of lipid status in postmenopausal women. Central Eur J Med 2012;7:642-9.

16. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: The Framingham study. J Bone Miner Res 1993;8:567-73.

17. Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteopor Int 1994;4:245-52.

18. Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Calcium intake and bone mineral density in older men and women: The Rancho Bernardo study. J Bone Miner Res 2015;31:6:6:55-62.

19. Khatake PD, Jadhav SS. A clinical study on serum calcium levels and bone mineral density in pre and postmenopausal Indian women. MedPulse Int Med J 2014;1:8:9.

20. Lavanya Y, Srikanth S, Satya C. Calcium intake and bone mineral density. JCMR 2014;6:13-9.

21. Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: The Rancho Bernardo study. J Bone Miner Res 2007;22:203-10.

22. Ali MR, Zaidan TF, Gorial FI. Validity of osteocalcin and alkaline phosphatase biomarkers in postmenopausal women with low bone mineral density. JCMR 2014;6:13-9.

23. Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, et al. Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 2004;15:981-91.

24. Nakamura Y, Suzuki T, Kato H. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. Ther Clin Risk Manag 2017;13:1343-8.

25. Moschikle L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990;19:35-63.

26. Udayakumar N, Chandrasekaran M, Rasheed MH, Suresh RV, Sivaparakash S. Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006;47:947-50.

27. Tsai KS, Lai SM, Huang KM, Chieng PU, Su CT, Chen FW. Decreased bone mineral density in patients with prolonged thyrotoxicosis before and after treatment. J Formos Med Assoc 1991;90:250-5.

28. Murphy E, Glüer CC, Reid DM, Felsenberg D, Roux C, Eastell R, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 2010;95:3173-81.

29. van Rijn LE, Pop VJ, Williams GR. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women. Eur J Endocrinol 2014;170:461-8.

30. Mundy GR, Shapiro JL, Bandelin JG, Canals EM, Raisz LG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 1976;58:529-34.

31. Parhami F. Possible role of oxidized lipids in osteoporosis: Could hyperlipidemia be a risk factor? Prostaglandins Leukot Essent Fatty Acids 2003;68:373-8.

32. Makovey J, Chen JS, Hayward C, Williams FM, Sambrook PN. Association between serum cholesterol and bone mineral density. Bone 2009;44:208-13.

33. Amer AE, Askar AF, El-Hamad HI. Impact of high serum lipid levels and ectopic fat mass on bone density in obese and non-obese hyperlipidemic middle age women. Int J Endocrinol Med Sci 2015;2:172-80.

34. Garg MK, Marwaha RK, Tandon N, Bhadra K, Mahalil N. Relationship of lipid parameters with bone mineral density in Indian population. Indian J Endocrinol Metab 2014;18:325-32.

35. Yamaguchi T, Sugimoto T, Yano S, Yamuchi M, Sowa H, Chen Q, et al. Plasma lipids and osteoporosis in postmenopausal women. Endo J 2002;49:211-7.

36. Ghadiri-Anari A, Mortezazi-Shoroki Z, Modarresi M, Delghaian A. Association of lipid profile with bone mineral density in postmenopausal women in Yazd province. Int J Reprod Biomed (Yazd) 2016;14:597-602.

37. Solomon DH, Avorn J, Canning CF, Wang PS. Lipid levels and bone mineral density. Am J Med 2005;118:1414.

38. Chen YY, Wang WW, Yang L, Chen WW, Zhang HX. Association between lipid profiles and osteoporosis in postmenopausal women: A meta-analysis. Eur Rev Med Pharmacol Sci 2018;22:1-9.

39. Wang Z, Li Y, Zhou F, Piao Z, Hao J. Effects of statins on bone mineral density and fracture risk: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3042.

40. Heidari B, Muvahandi A, Javadian Y, Bijani A, Hosseini R, Babaei M. Associated factors of bone mineral density and osteoporosis in elderly males. Int J Endocrinol Metab 2017;15:e39662.